Activity of cabozantinib after immunotherapy in advance kidney cancer

A retrospective study published in the European Journal of Cancer this month looked at the activity of cabozantinib after immune checkpoint inhibitors in people with metastatic clear cell renal cell carcinoma (RCC). The overall response rate was 36%, with a median overall survival of 13 months. Cabozantinib appeared to be well tolerated and there were […]

read more

Inflammatory biomarkers to predict outcomes in kidney cancer

There still remains the need for a reliable biomarker to predict outcomes for advanced kidney cancer patients. Scientists have been working hard to try to identify biomarkers that can predict clinical outcomes and the course of the disease in people with metastatic renal cell carcinoma (RCC). A recent study published in Pathology Oncology Research this […]

read more

ASCO 2020: Implications of the research presented at ASCO 2020 on the treatment of advanced kidney cancer

In this video presentation, Dr Toni Chouieri discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies, all of which were presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Programme. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma […]

read more

Sunitinib re-challenge in patients with metastatic kidney cancer

A study published in Clinical Genitourinary Cancer looks at the treatment of patients with metastatic RCC with sunitinib after they have already been treated with sunitinib and have stopped responding. Sunitinib is the standard of care for patients with metastatic RCC. However, nearly all patients will eventually stop responding to treatment with sunitinib and develop […]

read more

Systemic therapy for the treatment of metastatic kidney cancer brain metastases

Research published in Clinical Genitourinary Cancer┬áthis month looked at the use of systemic therapy for the treatment of patients with spread of metastatic renal cell carcinoma (RCC) to the brain (brain metastases). In recent years, the use of modern radiotherapy has resulted in significant improvements in the control and overall survival of RCC that has […]

read more

Cryoablation comparable to surgery for treating early-stage kidney cancer

A study published in the journal Radiology from John Hopkins University in Baltimore, America provides evidence that cryoablation is as effective as surgery for treating early-stage kidney cancer as evidenced from 10-year survival rates. Percutaneous cryoablation is a minimally invasive procedure that destroys cancer cells by freezing the tumour using a probe inserted through the […]

read more

Immune-related adverse events and clinical outcome in kidney cancer treated with nivolumab

In a paper published in Clinical Genitourinary Cancer the link between immune-related adverse events and clinical outcomes in patients with metastatic renal cell carcinoma (RCC) was investigated. One hundred and sixty seven (167) patients were included in the study. Of these, 46% had an immune-related adverse event, of which 8.9% were severe or life-threatening. However, […]

read more

ASCO 2020: Subtypes of kidney cancer differ in sites of metastases

A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]

read more

Bone metastases are associated with poor prognosis in papillary kidney cancer

A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]

read more

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

read more
Showing 1 to 10 of 108 results
  TOP